An announcement from Kiniksa Pharmaceuticals (KNSA) is now available.
Kiniksa Pharmaceuticals, Ltd. has announced the launch of a Phase 2b clinical trial for abiprubart in Sjogren’s Disease, along with promising topline data from its rheumatoid arthritis trial. The company also anticipates maintaining a positive cash flow within its current operations. This information, aimed at investors, has been made available through a press release and a detailed investor presentation on their website.
See more insights into KNSA stock on TipRanks’ Stock Analysis page.
